PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E of 0.00 while CRVO has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
14.29
Dangerously higher net debt above 1.5x CRVO's 2.18. Jim Chanos would check for potential debt spiral risks.
-147.54
Negative coverage while CRVO shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
12.94
Current ratio 1.25-1.5x CRVO's 11.36. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.